SCHEDULE: BioNexus Gene Lab Corp: CEO Awarded Shares

BioNexus Gene Lab Corp. CEO Su-Leng Tan Lee received a stock-based award of 338,709 shares as compensation for services, increasing beneficial ownership to 11.5%.

Summary

• Su-Leng Tan Lee, CEO and President of BioNexus Gene Lab Corp., was granted 338,709 shares of Common Stock.
• The shares were awarded under the 2025 Equity Incentive Plan as compensation for completed services and are fully vested.
• No cash consideration was paid for these shares; the award's value was based on the Nasdaq closing price of $1.55 per share on August 12, 2026, totaling $524,998.95.
• This award increases Su-Leng Tan Lee's beneficial ownership to 338,709 shares, representing approximately 11.5% of the outstanding Common Stock as of August 13, 2026.
• The transaction occurred offshore in reliance on Regulation S, with a six-month resale compliance period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it reflects compensation for services rendered rather than a new investment or strategic shift.

Positives

• CEO compensation for services rendered, aligning management interests with shareholders.
• Increase in beneficial ownership by the CEO to 11.5%, demonstrating commitment.
• Awarded shares are fully vested, providing immediate benefit for past services.

Negatives

• The shares were awarded for services and not purchased with personal funds, indicating no new capital investment by the CEO.
• A six-month resale compliance period under Regulation S may restrict immediate liquidity for the awarded shares.

Risks

• The shares are subject to transfer restrictions required for reliance on Regulation S.
• The Issuer has no obligation to register the shares for resale or assure liquidity.

Future Outlook

The Reporting Person may review the investment on a continuing basis and may change this intention in light of future developments. Any actions concerning the Issuer's business, operations, governance, capital structure, securities, financing, acquisitions or dispositions, Board composition, executive leadership and other matters would be subject to fiduciary duties, applicable law, and Issuer's governing documents.

Management Comments

• The award was separately approved on a basis for completed services and for no cash consideration.
• The Reporting Person acquired the shares as compensation for completed services to the Issuer and in connection with the Reporting Person's service as Chief Executive Officer and President and as a director.
• The Reporting Person has no present plan or proposal that relates to or would result in any action specified in Item 4(a) through (j) of Schedule 13D, except as described in this statement and in the Reporting Person's ordinary exercise of responsibilities as an executive officer and director.

Industry Context

StockSavvy.ai notes that stock-based compensation is a common practice in the biotechnology and diagnostics sector to attract and retain key talent, especially in growth-oriented companies. This award aligns with industry norms for executive remuneration.

Stakeholder Impact

• Shareholders: Increased CEO ownership may signal commitment, but the award is compensation, not new investment.
• Employees: The award is part of the company's incentive plan, potentially influencing morale and retention.
• Management: Direct alignment of CEO's financial interests with the company's stock performance.

Next Steps

• The Reporting Person may review the investment on a continuing basis and may change intentions based on future developments.
• Any future actions concerning the Issuer's business, operations, governance, capital structure, securities, financing, acquisitions or dispositions, Board composition, executive leadership and other matters will be subject to fiduciary duties, applicable law, and Issuer's governing documents.

Key Dates

Keywords

stock award, CEO compensation, equity incentive plan, beneficial ownership, Regulation S, corporate governance